News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
NICE’s highly specialised technologies programme has recommended Alexion’s monoclonal antibody (mAb) Soliris despite receiving no justification for the £340,000 ($513,000) price per patient.
ThermoFisher has forecast flat sales and earnings in 2015, warning that weaker currencies in key markets will offset higher biopharma spending.
Valeant is set to buy Dendreon’s prostate cancer drug Provenge as an economic way to enter the personalised oncology market.